| A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest. | |
| | |
MedLine Citation:
|
PMID: 11561689 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
JM216 is an orally administered platinum analogue. We undertook this study to determine the maximally tolerated dose (MTD) of JM216 when administered with concomitant radiotherapy to the chest (200 cGy daily, 5 x/week) in patients with locoregionally advanced non-small cell lung (NSCLC) or esophageal cancer. Patients were excluded for inadequate bone marrow reserve, prior radiotherapy to the primary tumor or previous treatment with platinum drugs. A dose-limiting toxicity (DLT) was defined using the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) and consisted of grade > or = 2 renal, hepatic, cardiac, or pulmonary toxicity or grade > or = 3 hematologic, neurological, or gastrointestinal toxicity. A total of 23 patients were registered; two never received treatment and are excluded from analyses. Six patients were treated at a dose of 30 mg/m2/day for 5 days with two grade 2 DLT's: cough (1 pt) and elevated trans-aminases (1 pt). Seven evaluable patients were treated at 60 mg/m2/day and seven experienced grade 3 or 4 toxicity, five related to myelosuppression. The dose was then reduced to 45 mg/m2/d. Eight patients were evaluable for toxicity, of which 5 experienced DLT: myelosuppression (3 pts), esophagitis (2 pts), dyspnea (1 pt), and elevated creatinine (1 pt). Fourteen patients were evaluable for efficacy, of which 6 had an objective response, including one complete response. The recommended phase II dose of JM216 with concurrent radiation therapy is 30 mg/m2/d for 5 days. The major DLT is myelosuppression with only limited increased toxicity within the field of radiation. This conceivably may limit the use of JM216 as a radiation sensitizer. |
| | |
Authors:
|
C M George; D J Haraf; A M Mauer; S A Krauss; P C Hoffman; C M Rudin; L Szeto; E E Vokes |
Related Documents
:
|
22028519 - A rare case of unusual gingival enlargement post radiotherapy. 1428729 - Phase i clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyiso... 3163529 - A phase ii study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer. 3786819 - Weekly-dose doxorubicin (wda) in advanced breast cancer. 8422699 - Phase i clinical evaluation of [sp-4-3(r)]-[1,1-cyclobutanedicarboxylato(2-)](2-methyl-... 21741829 - Trastuzumab beyond progression: overall survival analysis of the gbg 26/big 3-05 phase ... 19866239 - Cks1b overexpression implicates clinical aggressiveness of hepatocellular carcinomas bu... 12494249 - Thermoradiotherapy for local control of chest wall invasion in patients with advanced n... 23500609 - Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian... |
Publication Detail:
|
Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Investigational new drugs Volume: 19 ISSN: 0167-6997 ISO Abbreviation: Invest New Drugs Publication Date: 2001 |
Date Detail:
|
Created Date: 2001-09-19 Completed Date: 2002-03-12 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 8309330 Medline TA: Invest New Drugs Country: United States |
Other Details:
|
Languages: eng Pagination: 303-10 Citation Subset: IM |
Affiliation:
|
Section of Hematology/Oncology, University of Chicago, IL, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Aged Antineoplastic Agents / administration & dosage* Blood Cell Count Carcinoma, Non-Small-Cell Lung / drug therapy, radiotherapy Combined Modality Therapy Creatinine / analysis Dose-Response Relationship, Drug Esophageal Neoplasms / drug therapy*, radiotherapy Female Humans Lung Neoplasms / drug therapy*, radiotherapy* Male Maximum Tolerated Dose Middle Aged Organoplatinum Compounds / administration & dosage* Radiation Pneumonitis Radiotherapy Dosage |
| Grant Support | |
ID/Acronym/Agency:
|
P30CA14599/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Organoplatinum Compounds; 129580-63-8/satraplatin; 60-27-5/Creatinine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Gene expression profiling of exposure to TZT-1027, a novel microtubule-interfering agent, in non-sma...
Next Document: Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the he...